|
1
|
Wexler LH: Metastatic rhabdomyosarcoma:
Still room for improvement. J Clin Oncol. 34:105–106. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shern JF, Chen L, Chmielecki J, Wei JS,
Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, et
al: Comprehensive genomic analysis of rhabdomyosarcoma reveals a
landscape of alterations affecting a common genetic axis in
fusion-positive and fusion-negative tumors. Cancer Discov.
4:216–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hettmer S, Li Z, Billin AN, Barr FG,
Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ,
Houghton PJ, et al: Rhabdomyosarcoma: Current challenges and their
implications for developing therapies. Cold Spring Harb Perspect
Med. 4:a0256502014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arnold MA and Barr FG: Molecular
diagnostics in the management of rhabdomyosarcoma. Expert Rev Mol
Diagn. 17:189–194. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Belyea B, Kephart JG, Blum J, Kirsch DG
and Linardic CM: Embryonic signaling pathways and rhabdomyosarcoma:
Contributions to cancer development and opportunities for
therapeutic targeting. Sarcoma. 2012:4062392012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weigel BJ, Lyden E, Anderson JR, Meyer WH,
Parham DM, Rodeberg DA, Michalski JM, Hawkins DS and Arndt CA:
Intensive multiagent therapy, including dose-compressed cycles of
ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide,
irinotecan and radiation, in patients with high-risk
rhabdomyosarcoma: A report from the children's oncology group. J
Clin Oncol. 34:117–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zenitani M, Nojiri T, Uehara S, Miura K,
Hosoda H, Kimura T, Nakahata K, Miyazato M, Okuyama H and Kangawa
K: C-type natriuretic peptide in combination with sildenafil
attenuates proliferation of rhabdomyosarcoma cells. Cancer Med.
5:795–805. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ciccarelli C, Vulcano F, Milazzo L,
Gravina GL, Marampon F, Macioce G, Giampaolo A, Tombolini V, Di
Paolo V, Hassan HJ and Zani BM: Key role of MEK/ERK pathway in
sustaining tumorigenicity and in vitro radioresistance of embryonal
rhabdomyosarcoma stem-like cell population. Mol Cancer. 15:162016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marampon F, Gravina GL, Di Rocco A,
Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C,
Festuccia C, Popov VM, et al: MEK/ERK inhibitor U0126 increases the
radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by
downregulating growth and DNA repair signals. Mol Cancer Ther.
10:159–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu G, Zhou W, Zhao J, Pan X, Sun Y, Xu H,
Shi P, Geng C, Gao L and Tian X: Matrine alleviates
lipopolysaccharide-induced intestinal inflammation and oxidative
stress via CCR7 signal. Oncotarget. 8:11621–11628. 2017.PubMed/NCBI
|
|
11
|
Sun D, Wang J, Yang N and Ma H: Matrine
suppresses airway inflammation by downregulating SOCS3 expression
via inhibition of NF-κB signaling in airway epithelial cells and
asthmatic mice. Biochem Biophys Res Commun. 477:83–90. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie SB, He XX and Yao SK: Matrine-induced
autophagy regulated by p53 through AMP-activated protein kinase in
human hepatoma cells. Int J Oncol. 47:517–526. 2015.PubMed/NCBI
|
|
13
|
Li H, Li X, Bai M, Suo Y, Zhang G and Cao
X: Matrine inhibited proliferation and increased apoptosis in human
breast cancer MCF-7 cells via upregulation of Bax and
downregulation of Bcl-2. Int J Clin Exp Pathol. 8:14793–14799.
2015.PubMed/NCBI
|
|
14
|
Ma K, Huang MY, Guo YX and Hu GQ:
Matrine-induced autophagy counteracts cell apoptosis via the ERK
signaling pathway in osteosarcoma cells. Oncol Lett. 12:1854–1860.
2016.PubMed/NCBI
|
|
15
|
Guo L, Xue TY, Xu W and Gao JZ: Matrine
promotes G0/G1 arrest and down-regulates cyclin D1 expression in
human rhabdomyosarcoma cells. Panminerva Med. 55:291–296.
2013.PubMed/NCBI
|
|
16
|
Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q and
Su C: Anti-tumor activities of matrine and oxymatrine: literature
review. Tumour Biol. 35:5111–5119. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Herrero A, Pinto A, Colón-Bolea P, Casar
B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P,
Valdizán EM, et al: Small molecule inhibition of ERK dimerization
prevents tumorigenesis by RAS-ERK pathway oncogenes. Cancer Cell.
28:170–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang HQ, Jin JJ and Wang J: Matrine
induces mitochondrial apoptosis in cisplatin-resistant non-small
cell lung cancer cells via suppression of β-catenin/survivin
signaling. Oncol Rep. 33:2561–2566. 2015.PubMed/NCBI
|
|
19
|
Wu J, Hu G, Dong Y, Ma R, Yu Z, Jiang S,
Han Y, Yu K and Zhang S: Matrine induces Akt/mTOR signalling
inhibition-mediated autophagy and apoptosis in acute myeloid
leukaemia cells. J Cell Mol Med. 21:1171–1181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niu H, Zhang Y, Wu B, Zhang Y, Jiang H and
He P: Matrine induces the apoptosis of lung cancer cells through
downregulation of inhibitor of apoptosis proteins and the Akt
signaling pathway. Oncol Rep. 32:1087–1093. 2014.PubMed/NCBI
|
|
21
|
Li Y, Zhang ZN, Zhao HM, Tong ZC, Yang J,
Wang H and Liang XJ: Matrine inhibits the invasive properties of
human osteosarcoma cells by downregulating the ERK-NF-κB pathway.
Anti-Cancer Drugs. 25:1035–1043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qian L, Liu Y, Xu Y, Ji W, Wu Q, Liu Y,
Gao Q and Su C: Matrine derivative WM130 inhibits hepatocellular
carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling
pathways. Cancer Lett. 368:126–134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marampon F, Bossi G, Ciccarelli C, Di
Rocco A, Sacchi A, Pestell RG and Zani BM: MEK/ERK inhibitor U0126
affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
Mol Cancer Ther. 8:543–551. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guenther MK, Graab U and Fulda S:
Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK
pathway inhibition in rhabdomyosarcoma. Cancer Lett. 337:200–209.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Otabe O, Kikuchi K, Tsuchiya K, Katsumi Y,
Yagyu S, Miyachi M, Iehara T and Hosoi H: MET/ERK2 pathway
regulates the motility of human alveolar rhabdomyosarcoma cells.
Oncol Rep. 37:98–104. 2017.PubMed/NCBI
|
